• MK-0812 Workflows for CCR2-Driven MASH Research

  2026-08-11

  MK-0812 enables controlled interrogation of CCR2-dependent monocyte recruitment in gut–liver inflammation models. Its nanomolar whole-blood activity makes it useful for connecting intestinal TM6SF2 biology, hepatic immune-cell influx, and translational assay development without assuming that CCR2 blockade directly reproduces the study’s LPA intervention.

• MIZ1–TMBIM4 Control of IgG1+ GC B-Cell Selection

  2026-08-10

  This preprint identifies an immunoglobulin isotype-specific survival mechanism in germinal-center B cells: MIZ1 supports IgG1+ cell selection by inducing TMBIM4 and controlling BCR-triggered calcium mobilization. The findings connect transcriptional regulation, IP3 receptor signaling, mitochondrial integrity, and positive selection, providing a mechanistic framework for understanding why IgG1+ and IgM+ germinal-center cells do not have identical signaling dependencies.

• AO/PI Double Staining Kit Protocol Guide

  2026-08-09

  The AO/PI Double Staining Kit provides a rapid fluorescent cell viability assay that separates viable, apoptotic, and necrotic cell populations using Acridine Orange and Propidium Iodide. It is suitable for screening and routine cell-death assessment, but should not be treated as standalone proof of a specific apoptotic pathway or used for nonfluorescent readouts.

• DOTAP Workflows for Precision Gene Delivery

  2026-08-08

  Learn how DOTAP supports reproducible DNA, RNA, and antisense oligonucleotide delivery, from complex formation through transient or stable gene expression. The workflow also shows how to evaluate DOTAP-containing formulations as candidates for localized, mitochondria-focused delivery inspired by a recent glaucoma microneedle study.

• FK866 (APO866) Workflows for NAD-Targeted Research

  2026-08-07

  FK866 (APO866) enables controlled interrogation of NAMPT-dependent NAD metabolism, with practical value in AML cytotoxicity studies, metabolic phenotyping, and resistance-model experiments. This workflow-focused guide connects dose-response design, mitochondrial readouts, and the NAD biology of PARP inhibitor resistance while separating established evidence from testable hypotheses.

• Oltipraz: Optimizing Nrf2 Pathway Activation in MASLD Models

  2026-08-07

  Oltipraz, a 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, enables robust, reproducible Nrf2 pathway activation and phase II enzyme induction for chemoprevention and metabolic liver disease research. This article synthesizes cutting-edge workflows, troubleshooting, and translational strategies, building on recent breakthroughs in autophagy and ferroptosis modulation.

• ATRA Sensitizes Ovarian Cancer to PARP Inhibitors Post-Cispl

  2026-08-06

  This study demonstrates that all-trans retinoic acid (ATRA) can reverse platinum-induced resistance to PARP inhibitors in epithelial ovarian cancer (EOC) models. By downregulating key resistance-associated genes and intracellular NAD+ levels, ATRA enhances the efficacy of PARP inhibition and suggests a promising combinatorial maintenance strategy for EOC.

• Anti Reverse Cap Analog (ARCA): Translational Control for Ne

  2026-08-06

  Explore how Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G empowers translational control in mRNA synthesis. This article uniquely connects ARCA's molecular design to metabolic regulation insights, offering nuanced assay guidance for advanced mRNA research.

• CA-074 Me: Strategic Cathepsin B Inhibition for Lysosomal De

  2026-08-05

  Explore how CA-074 Me, a potent cathepsin B inhibitor, enables precise dissection of lysosomal membrane permeabilization and regulated cell death. This article uniquely bridges mechanistic insight with practical assay strategy for advanced apoptosis and inflammation research.

• Bradford Protein Assay Kit: Technical Guide for Reliable Qua

  2026-08-05

  The Bradford Protein Assay Kit (SKU: K4103) enables rapid, sensitive, and accurate protein concentration measurement in research samples, streamlining workflows that require fast turnaround and minimal sample usage. It is well suited for clear samples in applications like enzyme assays, protein purification, and molecular biology, but should not be used with samples containing high levels of detergents or reducing agents due to known assay interferences.

• Z-IETD-FMK: Specific Caspase-8 Inhibitor for Apoptosis Resea

  2026-08-04

  Z-IETD-FMK (Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone) is a potent, irreversible inhibitor of caspase-8, widely used to dissect apoptosis and immune cell activation mechanisms. Its specificity enables precise modulation of T cell proliferation and NF-κB signaling without affecting resting cells. This product dossier clarifies its validated applications and boundaries in apoptosis research.

• HyperScribe T7 High Yield Cy5 RNA Labeling Kit: Precision Pr

  2026-08-04

  The HyperScribe T7 High Yield Cy5 RNA Labeling Kit empowers researchers with unmatched flexibility and yield in fluorescent RNA probe synthesis. Its tunable Cy5-UTP incorporation and robust T7 polymerase mix enable reproducible, high-sensitivity detection for in situ and Northern blot hybridization—making it a preferred choice for demanding molecular biology workflows.

• Fluorene-9-Bisphenol Inhibits GPER: Mechanisms in Neuroblast

  2026-08-03

  This study uncovers a novel mechanism by which fluorene-9-bisphenol (BHPF), a common BPA substitute, inhibits G protein-coupled estrogen receptor 1 (GPER/GPER30) in human neuroblastoma cells. Integrating molecular simulations and cell-based assays, the research demonstrates BHPF’s direct antagonism of GPER, providing new insight into estrogen signaling disruption and potential neurotoxicity.

• BRD4770 and G9a Inhibition: Transforming Epigenetic Cancer M

  2026-08-03

  This thought-leadership article explores how BRD4770, a G9a histone methyltransferase inhibitor, is reshaping translational cancer research. By connecting mechanistic insights on the c-MYC/G9a/FTH1 axis and histone H3K9 methylation to experimental workflows and strategic therapeutic innovation, we provide translational researchers with actionable guidance. The discussion integrates recent clinical findings, competitive landscape analysis, and protocol recommendations while advancing beyond standard product descriptions.

• OTULIN-R57C Mutation Defines Isolated Pyoderma Gangrenosum M

  2026-08-02

  This study uncovers a homozygous OTULIN-R57C mutation as a genetic cause of isolated, pediatric-onset pyoderma gangrenosum (PG). Through precise molecular and cellular characterization, the paper elucidates how uncoupling OTULIN catalytic activity from LUBAC binding drives pathogenic IL-1β and TNF signaling, suggesting new therapeutic targets.

545 records 8/37 page Previous Next First page 上5页 678910 下5页 Last page